Anaerobic Blood Storage and Pathogen Inactivation Method
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/US2017/034410, filed May 25, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,583,192 | Anaerobic Blood Storage and Pathogen Inactivation Method In force · Low confidence | Hemanext Inc. | In force | Low confidence | ||
| US 11,147,876 | Anaerobic Blood Storage and Pathogen Inactivation Method In force · High confidence | Hemanext Inc. | In force | High confidence | ||
| US 11,911,471 | Anaerobic Blood Storage and Pathogen Inactivation Method In force · High confidence | Hemanext Inc. | In force | High confidence | ||
| US 12,364,760 | Anaerobic Blood Storage and Pathogen Inactivation Method In force · Medium confidence | Hemanext Inc. | In force | Medium confidence | ||
| Application 19/244,365 | Anaerobic Blood Storage and Pathogen Inactivation Method Pending Not granted | Hemanext Inc. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Hemanext Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.